ライフサイエンスコーパス: parkinsonism

1 nd 16 [3.5%] of multiple system atrophy with parkinsonism).

2 n some cases of frontotemporal dementia with parkinsonism.

3 syndrome of infantile/juvenile dystonia and parkinsonism.

4 gerated throughout basal ganglia circuits in parkinsonism.

5 individuals classified as having subclinical parkinsonism.

6 ning is associated with an increased risk of parkinsonism.

7 ity, possible RBD, smoking, and subthreshold parkinsonism.

8 0), a gene that is associated with recessive Parkinsonism.

9 role of the lysosome in the pathogenesis of parkinsonism.

10 AP) in a cohort of patients with early-stage parkinsonism.

11 re discovered to be associated with atypical parkinsonism.

12 Bank criteria, without exclusion of familial parkinsonism.

13 tients with Gaucher disease with and without parkinsonism.

14 he study of progressive neurodegeneration in parkinsonism.

15 ing of iMSNs characterize symptomatic rodent parkinsonism.

16 lear, is essential to understand its role in parkinsonism.

17 erturbed endosomal cargo sorting in atypical parkinsonism.

18 hich are linked to rare forms of early-onset Parkinsonism.

19 (DAT) cause a syndrome of infantile dystonia/parkinsonism.

20 he development of familial manganese-induced parkinsonism.

21 ulness as a diagnostic tool in patients with parkinsonism.

22 in a 6-hydroxydopamine (6-OHDA) rat model of parkinsonism.

23 ive diseases of the motor system or atypical parkinsonism.

24 eurological deficits, including dystonia and parkinsonism.

25 ltiple deletions, and altered mitophagy with parkinsonism.

26 w-up, patients were assessed for dementia or parkinsonism.

27 logous to some symptoms reported in INCL and parkinsonism.

28 tients with Parkinson's disease and atypical parkinsonism.

29 ting the pathological firing associated with parkinsonism.

30 ning mitochondrial integrity and suppressing Parkinsonism.

31 erns include the potential for akathisia and Parkinsonism.

32 the majority of autosomal recessive juvenile Parkinsonism.

33 ith autosomal recessive early-onset dystonia-parkinsonism.

34 te a role for PPTg in the pathophysiology of parkinsonism.

35 rders, including cerebral palsy and juvenile parkinsonism.

36 dentified in family members with adult-onset parkinsonism.

37 at higher risk to develop neurodegenerative parkinsonism.

38 nts in our case series presented symptoms of parkinsonism.

39 e mutations to neurodegenerative early-onset parkinsonism.

40 on to be a possible new cause of early-onset parkinsonism.

41 extrapyramidal clinical disorders, including parkinsonism.

42 erentiates Parkinson's disease from atypical parkinsonism.

43 aintenance of excessive beta oscillations in parkinsonism.

44 genicity of rare UQCRC1 variants in familial parkinsonism.

45 r for presumed synucleinopathy etiologies in parkinsonism.

46 those converting to primary dementia versus parkinsonism.

47 d motor phenotype in the MPTP mouse model of parkinsonism.

48 ase with adult onset dystonia and subsequent parkinsonism.

49 eriphery can result in neurodegeneration and parkinsonism.

50 on disease and the various forms of atypical parkinsonism.

51 syndromes and the treatment of drug-induced parkinsonism.

52 with dementia, 1285 with stroke and 263 with parkinsonism.

53 le mice treated with the MPTP, as a model of parkinsonism.

54 his pathway is compromised in a rat model of Parkinsonism.

55 cerebrosidase (GCase), are a risk factor for parkinsonism.

56 erated in cortical-basal ganglia circuits in parkinsonism.

57 nition of patients with Gaucher disease with parkinsonism.

58 or symptoms of Parkinson's disease and other parkinsonisms.

59 the 2000 subcohort, we observed 28 cases of parkinsonism (10 with PD) during 22,307 person-years.

60 were 128 nondemented patients with new-onset parkinsonism (104 with PD, 11 with multiple system atrop

61 nd seizures (2.8%, 0.5-5.9) and moderate for parkinsonism (11.2%, 5.3-17.1).

62 ribed signs were movement disorders, such as parkinsonism (12%) and dystonia (19%).

63 .6-22.2 and 15.0%, 12.5-17.6, respectively), parkinsonism (12.5%, 10.1-15.0), and seizures (20.3%, 17

64 , aripiprazole was also associated with more Parkinsonism (15 [17%] of 86 vs two [2%] of 81 participa

65 Among patients with incident parkinsonism, 24 (30.4%) also developed dementia (10 bef

66 similar for stroke (19.0%vs18.9% in men) and parkinsonism (3.3% vs 3.6% in men).

67 ctive cohort of 60 patients with early-stage parkinsonism (39 PD, 21 AP).

68 Of 906 patients with parkinsonism, 501 were men, and the median age at onset

69 4 years) compared to multiple system atrophy-parkinsonism (62.3 years; P < 0.001).

70 the 1990 subcohort, there were 182 cases of parkinsonism (84 of which were PD) during 57,052 person-

71 s of the disorder were identified, including parkinsonism (95.2% of patients), depression/apathy (71.

72 Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Par

73 mer disease (AD)-affected families and three parkinsonism-affected families, implicating that the GGC

74 ls and extends beyond patients with onset of parkinsonism after dementia.

75 erse events (AEs) and scales used to monitor parkinsonism, akathisia/restlessness, anxiety, depressio

76 including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury

77 We named this disinhibition-dementia-parkinsonism-amyotrophy complex.

78 cts were classified as level I indeterminate parkinsonism and 4 more subjects as level II indetermina

79 n DCTN1; or a family history of the disease, parkinsonism and a mutation in DCTN1; or the presence of

80 tants linked to frontotemporal dementia with parkinsonism and alpha-synuclein by increasing their sec

81 Parkinsonism and attention deficit hyperactivity disorde

82 in 62 isolated individuals with early-onset parkinsonism and confirmed consanguinity followed by dat

83 ants of the Rotterdam Study who were free of parkinsonism and dementia.

84 ternal ophthalmoplegia (CPEO) complicated by parkinsonism and dementia.

85 f each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy.

86 een linked to symptoms of the early onset of Parkinsonism and Dystonia.

87 ation frequencies >100 Hz, commonly used for parkinsonism and essential tremor, worsened incoordinati

88 ement and timing of limbs in mouse models of parkinsonism and human PD subjects at speeds that are re

89 3 modifies age of onset for LRRK2 Gly2019Ser parkinsonism and informs disease-relevant translational

90 displaying clinical features of early-onset parkinsonism and intellectual disability identified a ap

91 c transmission, but its role in experimental Parkinsonism and l-DOPA responses has been neglected.

92 ease mutation manifest a clinical picture of parkinsonism and Lewy body dementia, and E46K creates mo

93 anguage impairment and sometimes features of parkinsonism and motor neuron disease.

94 opathological subtypes: MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia,

95 ive development of intention tremor, ataxia, parkinsonism and neuropsychological problems.

96 These alpha-synucleinopathies have in common parkinsonism and non-motor features including orthostati

97 We investigated trends in the incidence of parkinsonism and Parkinson disease (PD) by comparing dat

98 Changes over time in the incidence of parkinsonism and Parkinson disease (PD) remain uncertain

99 Our study suggests that the incidence of parkinsonism and PD may have increased between 1976 and

100 Incidence rates of parkinsonism and PD over 30 years.

101 Subthreshold parkinsonism and physical activity showed an interaction

102 family with a late-onset autosomal-dominant parkinsonism and polyneuropathy.

103 hydropyridine-treated macaques with advanced parkinsonism and reproducible LID received a range of na

104 of the molecular basis of PD mimetic-induced Parkinsonism and the discovery of neuroprotective agents

105 r neuropathies, spinal muscular atrophy with parkinsonism and the later stages can resemble amyotroph

106 f (18)F-FDG PET for diagnostic evaluation of parkinsonism and the promising role of (18)F-FDG PET for

107 To study how glucocerebrosidase impacts parkinsonism and to evaluate new therapeutics, we genera

108 tonomic failure along with motor symptoms of parkinsonism and/or cerebellar ataxia.

109 pastic paraplegia accompanied by neuropathy, parkinsonism and/or cognitive impairment.

110 istinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3

111 heterozygous GBA1 mutation carriers (15 with parkinsonism) and 98 controls looking for early indicati

112 of gait is a major risk factor for falls in parkinsonism, and a source of disability to patients.

113 derivations of this) to identify subclinical parkinsonism, and association of risk estimates with MDS

114 sease include progressive autonomic failure, parkinsonism, and cerebellar ataxia leading to significa

115 thogenesis of amyotrophic lateral sclerosis, parkinsonism, and dementia in Guamanian Chamorros.

116 of an endolysosomal genetic defect linked to Parkinsonism, and highlight the presence of alpha-synucl

117 c) Gaucher disease, two with and two without parkinsonism, and one patient with Type 2 (acute neurono

118 k for Lewy body accumulation, progression of parkinsonism, and PD, but not dementia, AD, neuritic pla

119 ; P = .004) loci were associated with global parkinsonism, and these associations remained after excl

120 opamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valben

121 nsorineural deafness, peripheral neuropathy, parkinsonism, and/or cognitive impairment, in most cases

122 nce to differentiate between PD and atypical parkinsonism (AP) in a cohort of patients with early-sta

123 are mutated in autosomal-recessive juvenile Parkinsonism (AR-JP) and work together in the disposal o

124 Autosomal-recessive juvenile Parkinsonism (AR-JP) is caused by mutations in a number

125 early onset of autosomal-recessive juvenile parkinsonism (AR-JP), although the mechanisms by which a

126 netic changes specific for X-linked dystonia-parkinsonism are common in the Philippines, the epigenet

127 esting that signs of depressive disorders in parkinsonism are related to altered stress vulnerability

128 lation distribution of rare genetic forms of parkinsonism are required, now that gene-targeting appro

129 lation distribution of rare genetic forms of parkinsonism are required, now that gene-targeting appro

130 sms by which mutations in this protein cause parkinsonism are unclear.

131 tated in 50% of autosomal recessive juvenile parkinsonism (ARJP) cases.

132 revalence and genetic causes of dystonia and parkinsonism as well as radiological findings in the con

133 -effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndrom

134 disease, three frontotemporal dementia with parkinsonism associated with chromosome 17, three unclas

135 nant early amnesia and behavioural change or parkinsonism associated with the 'missing' +15 mutation

136 The ubiquitously expressed DJ-1 (Parkinsonism-associated deglycase) is known as a Parkins

137 Here, we found that the parkinsonism-associated protein DJ-1 and its bacterial h

138 Recently, the Parkinsonism-associated protein DJ-1 was described in vi

139 ow this interactome is perturbed in atypical parkinsonism-associated VPS26A mutants.

140 al DA-related disorders, including infantile parkinsonism, attention-deficit/hyperactivity disorder a

141 lation of manganese or of copper can lead to parkinsonism because of dopamine deficiency.

142 tudied lifetime risk of dementia, stroke and parkinsonism between 1990 and 2016.

143 ntal delay and developed levodopa-responsive parkinsonism between the ages of 25 and 40 years.

144 gression models to compare the incidences of parkinsonism, both overall and by cause (PD and secondar

145 erformed better on tests of motor speech and parkinsonism but more poorly, and declined faster over t

146 algorithm to classify subjects with clinical parkinsonism but uncertain diagnosis based on the expres

147 These features are also present in atypical parkinsonisms, but the sequence effect is not common.

148 discharge before and after the induction of parkinsonism by administration of MPTP (1-methyl-4-pheny

149 e how dysregulation of their firing in early Parkinsonism can impair their effector circuits.

150 -localized manganese efflux transporter, and parkinsonism-causing mutations block its trafficking and

151 of autonomic failure, levodopa-unresponsive parkinsonism, cerebellar ataxia and pyramidal symptoms.

152 rder with symptoms of autonomic failure plus parkinsonism, cerebellar ataxia, or both.

153 ommon and disabling symptom in patients with parkinsonism, characterised by sudden and brief episodes

154 sociated with a distinct form of early-onset parkinsonism characterized by rapid and severe disease p

155 idered in families where amnesia or atypical parkinsonism coexists with behavioural disturbance early

156 ndividuals with multiple system atrophy with parkinsonism, dementia with Lewy bodies, and Parkinson d

157 sociated with amyotrophic lateral sclerosis, parkinsonism, dementia, and related neurodegenerative sy

158 were reviewed for clinical features such as parkinsonism, dementia, and vascular risk factors.

159 e cause of the amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC), or Alzheimer's

160 Amyotrophic lateral sclerosis/parkinsonism-dementia complex has been described in Guam

161 eurotoxins possibly responsible for atypical Parkinsonism/dementia clusters, via the consumption of e

162 The association of CPEO and parkinsonism/dementia with subclinical optic neuropathy

163 Lines generated from the patients with parkinsonism demonstrated elevated levels of alpha-synuc

164 Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacke

165 disorder characterised by clinical signs of parkinsonism, depression/apathy, weight loss, respirator

166 Patients with dementia diagnosis before parkinsonism diagnosis were considered to have probable

167 city of data on cognitive functioning before parkinsonism diagnosis, a stage at which patients may st

168 uorodopa uptake in mutation carriers without parkinsonism did not significantly differ from controls.

169 n three men will develop dementia, stroke or parkinsonism during their life.

170 Patients presenting with parkinsonism dystonia or a neurotransmitter profile char

171 redefined extrapyramidal movement disorders (parkinsonism, dystonia, tremor, chorea, and restless leg

172 sults in rapidly progressive childhood-onset parkinsonism-dystonia with distinctive brain magnetic re

173 es, including amyotrophic lateral sclerosis, parkinsonism, epilepsy, and hemiplegic migraine.

174 uld play a role in the diagnosis of atypical parkinsonism, especially in PSP.

175 ove the diagnostic accuracy in patients with parkinsonism, even at early disease stages.

176 er et al.) describe the development of acute parkinsonism following coronavirus disease 2019 (COVID-1

177 Five patients developed mild parkinsonism following deep brain stimulation.

178 Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010.

179 isease', 'Paradoxical kinesia', 'Psychogenic parkinsonism', 'Functional somatic syndromes', 'Chronic

180 In a mouse model of early parkinsonism, GATs are downregulated, tonic GABAergic in

181 analysis model to indicate that all forms of parkinsonism had elevated free-water in the substantia n

182 with Type 2 and Type 1 Gaucher disease with parkinsonism had reduced dopamine storage and dopamine t

183 hich is mutated in some types of early-onset Parkinsonism, has been suggested as a regulator of the a

184 sease, only a handful of monogenic causes of parkinsonism have been identified.

185 associated with a higher hazard of incident parkinsonism (hazard ratio [HR], 1.79; 95% CI, 1.37-2.33

186 Patients with multiple system atrophy with parkinsonism (hazard ratio, 10.51; 95% CI, 2.92-37.82) h

187 oving individuals with dementia onset before parkinsonism (HR, 1.72; 95% CI, 1.28-2.27).

188 igra pars compacta (SNpc) neurons alleviates parkinsonism in acute PD animal models by recovering tyr

189 There was continued progression of parkinsonism in both patients.

190 These findings suggest that the incidence of parkinsonism in general, and of PD in particular, decrea

191 f all changes specific for X-linked dystonia-parkinsonism in genomic DNA.

192 type tag for which the median onset of LRRK2 parkinsonism in GG carriers was 12.5 years younger than

193 HTRA2 and PINK1 loss of function causes parkinsonism in humans and animals.

194 he typical antipsychotic haloperidol induces parkinsonism in humans and catalepsy in rodents.

195 ss induced reversible symptoms that resemble parkinsonism in humans and in animal models raise the qu

196 fers to 'Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder:

197 ld SWI could identify prodromal degenerative parkinsonism in iRBD.

198 yl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism in nonhuman primates.

199 ify incidence cases of PD and other types of parkinsonism in Olmsted County, Minnesota, from 1976 to

200 ns was effective in treating the symptoms of parkinsonism in the 6-hydroxydopamine (6-OHDA) lesion ra

201 romosome inactivation is the likely cause of parkinsonism in this heterozygous mutation carrier.

202 0 to 44, with higher scores indicating worse parkinsonism) in the off-medication state.

203 ase from General Practice to Neurologist and Parkinsonism: Incidence, Cognition and Non-motor heterog

204 functions provoke the core motor syndrome of parkinsonism including freezing and failed gait automati

205 f PPTg in gait, developed a refined model of parkinsonism including partial loss of the PPTg with bil

206 tion is a common feature among patients with parkinsonism, including Parkinson disease (PD).

207 en implicated in neurological disorders with parkinsonism, including Parkinson's disease and Dementia

208 ssociated with an increased risk of incident parkinsonism, including probable PD.

209 ethyl-4-phenyl-1,2,3,6-tetrahydropyridine, a parkinsonism-inducing agent.

210 Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous

211 Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic

212 Accurate antemortem diagnosis of parkinsonism is primarily based on clinical evaluation w

213 excluding non-DLB dementias, especially when parkinsonism is the only "core feature" exhibited by the

214 e accuracy of diagnosis when the presence of parkinsonism is uncertain.

215 ly believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and

216 h experiments in humans and animal models of Parkinsonism, it is unclear how the pattern regularizati

217 c lateral sclerosis and rapid-onset dystonia parkinsonism, knowledge of their contribution to motor n

218 bilitating and often fatal form of infantile Parkinsonism known as AADC deficiency.

219 Constipation was lowest and subthreshold parkinsonism least frequent in individuals with the Prev

220 which can cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and can c

221 MAPT gene cause frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), characte

222 rders, including frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), which is

223 gene MAPT cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).

224 ein bearing two frontotemporal dementia with Parkinsonism linked to chromosome 17 pathogenic mutation

225 In experimental parkinsonism models, regression curves representing thes

226 (multiple-system atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C

227 (multiple-system atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C

228 yndrome; they showed a combination of severe parkinsonism, near mutism, dysphagia with choking, verti

229 Parkinsonism negatively covaried with bilateral parietal

230 most stringent published cut-off for subtle parkinsonism of three definitions examined (p=0.027).

231 rebrospinal fluid (CSF) of 118 patients with parkinsonism of uncertain clinical etiology and 52 contr

232 individuals received a diagnosis of incident parkinsonism; of these, 57 (72.2%) received a diagnosis

233 o developed dementia (10 before and 14 after parkinsonism onset).

234 found in patients with rapid-onset dystonia parkinsonism or alternating hemiplegia of childhood caus

235 tcomes were a quantitative measure of global parkinsonism or component measures of bradykinesia, rigi

236 polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cogniti

237 y elevated in neurons from the patients with parkinsonism or Type 2 Gaucher disease.

238 mentia, psychiatric disturbances, associated parkinsonism, or an autosomal dominant disorder is prese

239 emiplegia of Childhood, Rapid-onset Dystonia Parkinsonism, or epilepsy.

240 nce weekly for 3 weeks to induce features of Parkinsonism, or vehicle (control).

241 Cognition indicates the probability of parkinsonism over long intervals and extends beyond pati

242 r binding and the diagnosis of nigrostriatal parkinsonism, particularly PD.

243 entia and death) as well as the mortality of parkinsonism patients in the 2 subcohorts.

244 its Sac domain was identified in early-onset parkinsonism patients.

245 Hazard ratios (HRs) for incident parkinsonism per SD decrease in global cognition, adjust

246 enes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together i

247 2%), often in the context of Leigh syndrome; parkinsonism predominated in 13 adult patients (43%), am

248 ndrome (KRS) characterized by juvenile-onset parkinsonism, pyramidal signs and dementia.

249 of childhood (AHC), and rapid-onset dystonia parkinsonism (RDP) are caused by mutations of Na(+),K(+)

250 lysis, we previously derived and validated a parkinsonism-related metabolic pattern (PRP) in nonhuman

251 significantly over 30 years in men for both parkinsonism (relative risk [RR], 1.17 per decade; 95% C

252 hort, and mortality rates among persons with parkinsonism remained stable.

253 These results suggest that DJ-1-associated Parkinsonism results from excessive protein glycation an

254 or older, incidence rates increased for both parkinsonism (RR, 1.24 per decade; 95% CI, 1.07-1.44) an

255 obable multiple system atrophy-of either the parkinsonism subtype (MSA-P) or the cerebellar ataxia su

256 dopaminergic neurons from the patients with parkinsonism, suggesting that noninhibitory small-molecu

257 patients (patients without neurodegenerative parkinsonism syndromes and normal SPECT imaging) were in

258 he benefit of functional imaging in atypical parkinsonism syndromes remains unclear.

259 and reveal a maladaptive plasticity in early parkinsonism that impairs DA output in vulnerable striat

260 ased, prospective cohort study of idiopathic parkinsonism that included patients diagnosed between Ja

261 m of 10 years and monitored for the onset of parkinsonism, the onset of dementia, or death, until Jan

262 c nervous system function and often signs of parkinsonism; the neuropathological hallmark of MSA is g

263 In the paraquat-induced model of Parkinsonism, this nigro-vagal pathway was compromised d

264 d up until January 1, 2015, for the onset of parkinsonism through serial in-person examinations and c

265 ECT studies comparing patients with atypical parkinsonism to another diagnostic group (PD, MSA, PSP,

266 bute to the skewing of the sex prevalence of parkinsonism toward women in this country, warranting fu

267 ncluded in vivo behavioral measures of motor parkinsonism using a validated nonhuman primate rating s

268 tal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MS

269 uding motor subtype (multiple system atrophy-parkinsonism versus multiple system atrophy-cerebellar a

270 ienced a more rapid decline in her gait with parkinsonism, visual difficulties with restricted vertic

271 ventually developed apraxia of speech, while parkinsonism was absent-to-mild throughout all visits fo

272 sex-matched Olmsted County resident without parkinsonism was also identified.

273 Parkinsonism was defined as the (1) presence of hypokine

274 The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis.

275 e overall age- and sex-adjusted incidence of parkinsonism was lower in the 2000 subcohort (incidence

276 Parkinsonism was the most prevalent extrapyramidal movem

277 Multiple system atrophy-parkinsonism was the predominant subtype in 430 patients

278 Using experimental mouse models of Parkinsonism, we report here that global p11 knockout (K

279 onally relevant morphological alterations in parkinsonism, we used a combination of light and electro

280 nd right limbs before and after induction of parkinsonism, we used circular statistics.

281 Risk factors for primary dementia and parkinsonism were generally similar, except for a notabl

282 of DBS in the refined and standard model of parkinsonism were very different despite minimal behavio

283 alpha-synucleinopathies from other forms of parkinsonism when the clinical picture is uncertain.

284 ng of the pathways is altered in symptomatic parkinsonism, where iMSNs fire significantly more and ea

285 Some carriers have early-onset parkinsonism, whereas others remain asymptomatic despite

286 6) scores were each associated with incident parkinsonism, whereas the association with word learning

287 ke in 7 non-DLB subjects (3 with concomitant parkinsonism) who had normal (123) I-MIBG myocardial upt

288 directly associated with whether dystonia or parkinsonism will manifest at onset.

289 After induction of parkinsonism with 1-methyl-4-phenyl-1,2,3,6-tetrahydropy

290 s a cause of autosomal-recessive early-onset parkinsonism with a distinctive phenotype of rapid and s

291 syndrome (KRS), characterized by early-onset Parkinsonism with additional neurological features.

292 disorders, including Kufor-Rakeb syndrome-a parkinsonism with dementia(1)-and early-onset Parkinson'

293 multiplications were identified in familial parkinsonism with dementia.

294 at kinase 2 (LRRK2) cause autosomal-dominant Parkinsonism with pleomorphic pathology including deposi

295 She experienced worsening of parkinsonism with severe dyskinesias, and underwent subt

296 Clinically, the condition manifests as parkinsonism with the addition of progressive balance, s

297 We report the association of early-onset parkinsonism with the PPP2R5D p.E200K mutation.

298 X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease associ

299 X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease with a

300 X-linked dystonia parkinsonism (XDP) is a neurodegenerative movement disor